JP2003511412A5 - - Google Patents

Download PDF

Info

Publication number
JP2003511412A5
JP2003511412A5 JP2001529435A JP2001529435A JP2003511412A5 JP 2003511412 A5 JP2003511412 A5 JP 2003511412A5 JP 2001529435 A JP2001529435 A JP 2001529435A JP 2001529435 A JP2001529435 A JP 2001529435A JP 2003511412 A5 JP2003511412 A5 JP 2003511412A5
Authority
JP
Japan
Prior art keywords
acid
compound
group
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001529435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003511412A (ja
JP4780885B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/028250 external-priority patent/WO2001026645A1/en
Publication of JP2003511412A publication Critical patent/JP2003511412A/ja
Publication of JP2003511412A5 publication Critical patent/JP2003511412A5/ja
Application granted granted Critical
Publication of JP4780885B2 publication Critical patent/JP4780885B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001529435A 1999-10-12 2000-10-11 正常細胞を化学療法剤の細胞毒性から保護するための方法 Expired - Lifetime JP4780885B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15912399P 1999-10-12 1999-10-12
US60/159,123 1999-10-12
PCT/US2000/028250 WO2001026645A1 (en) 1999-10-12 2000-10-11 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents

Publications (3)

Publication Number Publication Date
JP2003511412A JP2003511412A (ja) 2003-03-25
JP2003511412A5 true JP2003511412A5 (enExample) 2007-11-22
JP4780885B2 JP4780885B2 (ja) 2011-09-28

Family

ID=22571170

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001529435A Expired - Lifetime JP4780885B2 (ja) 1999-10-12 2000-10-11 正常細胞を化学療法剤の細胞毒性から保護するための方法

Country Status (8)

Country Link
EP (1) EP1223923B1 (enExample)
JP (1) JP4780885B2 (enExample)
AT (1) ATE462423T1 (enExample)
AU (1) AU780844B2 (enExample)
CA (1) CA2387539C (enExample)
DE (1) DE60044092D1 (enExample)
IL (1) IL149064A0 (enExample)
WO (1) WO2001026645A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548553B2 (en) 1997-10-03 2003-04-15 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
CA2366750C (en) * 1999-04-02 2010-06-01 Temple University - Of The Commonwealth System Of Higher Education (e)-styryl sulfone anticancer agents
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
US6541475B2 (en) * 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
US7053123B2 (en) 2000-10-05 2006-05-30 Temple University-Of The Commonwealth System Of Higher Education Substituted (e)-styryl benzylsulfones for treating proliferative disorders
JP2004521126A (ja) 2001-02-27 2004-07-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション （ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用
EP1370253B8 (en) * 2001-02-28 2008-11-26 Temple University of the Commonwealth System of Higher Education Use of alpha, beta unsaturated aryl sulfones for protecting cells and tissues from ionizing radiation toxicity
WO2003072062A2 (en) * 2002-02-28 2003-09-04 Temple University-Of The Commonwealth System Of Higher Education Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
AU2004289281C1 (en) * 2003-11-14 2011-12-08 Onconova Therapeutics, Inc. Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders
WO2007016201A2 (en) * 2005-07-29 2007-02-08 Onconova Therapeutics, Inc. FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
WO2008076270A2 (en) 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
EP4001263B1 (en) * 2019-07-18 2024-03-27 Huaxiashengsheng Pharmaceutical Beijing Co., Ltd. Carbamate-substituted styryl sulfone compound, preparation method, and application thereof
CN111253935B (zh) * 2019-12-24 2022-12-13 安徽大学 一种双通道检测极性和粘度的双光子荧光探针及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
EP0439421A1 (de) * 1990-01-23 1991-07-31 Ciba-Geigy Ag Mikrobizide Mittel
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
CZ299718B6 (cs) * 1997-10-03 2008-10-29 Temple University - Of The Commonwealth System Ofhigher Education Styrylsulfonová sloucenina a farmaceutický prostredek ji obsahující

Similar Documents

Publication Publication Date Title
JP2003511412A5 (enExample)
JP2013540114A5 (enExample)
JP2009515980A5 (enExample)
JP2003520195A5 (enExample)
JP2005523922A5 (enExample)
AU1708202A (en) Organic compounds
CY1113270T1 (el) Παραγωγα φουρο [3,2-β] πυρρολ-3-ονης και η χρηση τους ως αναστολεων κυστεϊνυλ πρωτεϊνασης
JP2004516314A5 (enExample)
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
JP2005511547A5 (enExample)
JP2010505865A5 (enExample)
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
RU2008110644A (ru) Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
JP2008545695A5 (enExample)
CN105246483A (zh) 用于γ-谷氨酰循环调节的方法和组合物
RU2011108485A (ru) Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas
EP2030618A3 (en) Combinations comprising epothilones and anti-metabolites
JP2004538278A5 (enExample)
NO20052100L (no) Raloksifensalt I
JP2006500372A5 (enExample)
RU2009145537A (ru) Терапевтические соединения
RU2005130992A (ru) Производные сложноэфирных липидов нуклеотидов
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
MX2007008082A (es) Formulaciones farmaceuticas de sales de galio.